Nuvalent (NUVL) Enterprise Value (2020 - 2026)
Nuvalent's (NUVL) quarterly Enterprise Value came in at -$1.3 billion in Q1 2026, down 19.96% YoY from -$1.6 billion in Q1 2025, and up 6.16% on a QoQ basis from -$1.4 billion in Q4 2025.
Nuvalent (NUVL) Enterprise Value (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Enterprise Value data on file, last reported at -$1.3 billion in Q1 2026.
- Quarterly Enterprise Value fell 19.96% year-over-year to -$1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 billion (down 19.96% YoY) and the FY2025 annual result came in at -$1.4 billion, down 22.68% from the prior year.
- Enterprise Value rose to -$1.3 billion in Q1 2026, from -$1.4 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$257.0 million in Q2 2022 to a low of -$1.4 billion in Q4 2025.
- A 5-year average of -$749.3 million and a median of -$691.8 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value tumbled 182.71% — and 2025, when it gained 19.28%.
- Tracing NUVL's Enterprise Value over 5 years: stood at -$472.2 million in 2022, then slumped by 52.47% to -$719.9 million in 2023, then plunged by 55.34% to -$1.1 billion in 2024, then declined by 22.68% to -$1.4 billion in 2025, then gained by 6.16% to -$1.3 billion in 2026.
- The last three Enterprise Value figures came in at -$1.3 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$943.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | -1.29 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.29 Bn |
| Dec 31, 2025 | -1.37 Bn |
| Sep 30, 2025 | -943.10 Mn |
| Jun 30, 2025 | -1.01 Bn |
| Mar 31, 2025 | -1.07 Bn |
| Dec 31, 2024 | -1.12 Bn |
| Sep 30, 2024 | -1.17 Bn |
| Jun 30, 2024 | -657.99 Mn |
| Mar 31, 2024 | -691.84 Mn |
| Dec 31, 2023 | -719.91 Mn |
| Sep 30, 2023 | -413.26 Mn |
| Jun 30, 2023 | -431.24 Mn |
| Mar 31, 2023 | -450.46 Mn |
| Dec 31, 2022 | -472.16 Mn |
| Sep 30, 2022 | -402.81 Mn |
| Jun 30, 2022 | -256.96 Mn |
| Mar 31, 2022 | -272.73 Mn |
| Dec 31, 2021 | -288.11 Mn |
| Sep 30, 2021 | -302.43 Mn |
| Dec 31, 2020 | -10.33 Mn |